^
No biomarker
Biliary Tract Cancer
fosgemcitabine palabenamide
Sensitive: B - Late Trials
NuCana Press Release - 3 weeks
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
No biomarker
Gallbladder Cancer
GC
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
GemOx
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
GEM-CAP
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
FP
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
XP
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
FP
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
XP
Sensitive: A2 - Guideline
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gallbladder Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
cisplatin + gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
BRAF V600E
Biliary Tract Cancer
trametinib + dabrafenib
Sensitive: A2 - Guideline
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A2 - Guideline
NTRK3 fusion
Biliary Tract Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Biliary Tract Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Biliary Tract Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Biliary Tract Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Biliary Tract Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Biliary Tract Cancer
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
gemcitabine + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
gemcitabine + capecitabine
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
cisplatin + gemcitabine
Sensitive: A2 - Guideline
BRAF V600E
Biliary Tract Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
No biomarker
Biliary Tract Cancer
FOLFOX
Sensitive: A2 - Guideline
MSI-H/dMMR
Biliary Tract Cancer
dostarlimab
Sensitive: A2 - Guideline
No biomarker
Cholangiocarcinoma
infigratinib
Sensitive: B - Late Trials
HER-2 expression
Biliary Tract Cancer
ZW25
Sensitive: B - Late Trials
FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: B - Late Trials
FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: B - Late Trials
HER-2 expression
Cholangiocarcinoma
trastuzumab + lapatinib
Sensitive: B - Late Trials
RET fusion
Cholangiocarcinoma
pralsetinib
Sensitive: C1 - Off-label
MSI-H/dMMR
Gallbladder Cancer
dostarlimab
Resistant: C1 - Off-label
BRCA2 mutation
Cholangiocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA1 mutation
Cholangiocarcinoma
olaparib
Sensitive: C1 - Off-label
HER-2 overexpression
Gallbladder Cancer
trastuzumab
Sensitive: C1 - Off-label
FGFR3 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
MSI-H/dMMR
Gallbladder Cancer
pembrolizumab
Sensitive: C1 - Off-label
NTRK3 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK2 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
PD-L1 expression
Biliary Tract Cancer
pembrolizumab
Sensitive: C1 - Off-label
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
MSI-H/dMMR
Cholangiocarcinoma
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Biliary Tract Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
BRAF V600E
Cholangiocarcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
NTRK2 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
HER-2 positive
Biliary Tract Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: C1 - Off-label
BRAF V600E
Biliary Tract Cancer
trametinib
Sensitive: C1 - Off-label
BRCA2 mutation
Biliary Tract Cancer
olaparib
Sensitive: C1 - Off-label
ATM mutation
Biliary Tract Cancer
olaparib
Sensitive: C1 - Off-label
HER-2 positive
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
BRCA1 mutation
Gallbladder Cancer
olaparib
Sensitive: C1 - Off-label
FGFR2 translocation
Cholangiocarcinoma
pemigatinib
Sensitive: C2 – Inclusion Criteria
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 amplification
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Biliary Tract Cancer
gemcitabine
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
TAS 120
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
Cholangiocarcinoma
dasatinib
Sensitive: C2 – Inclusion Criteria
IDH1 R132C
Cholangiocarcinoma
ivosidenib
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Biliary Tract Cancer
M7824
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
Cholangiocarcinoma
metformin
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Biliary Tract Cancer
ZW25
Sensitive: C3 – Early Trials
HER-2 mutation
Biliary Tract Cancer
neratinib
Sensitive: C3 – Early Trials
MET amplification
Gallbladder Cancer
crizotinib
Sensitive: C3 – Early Trials
ERBB3 mutation
Gallbladder Cancer
lapatinib
Sensitive: C3 – Early Trials
HER-2 amplification
Gallbladder Cancer
trastuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Gallbladder Cancer
lapatinib
Sensitive: C3 – Early Trials
HER-2 amplification
Gallbladder Cancer
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
ATM mutation
Biliary Tract Cancer
toripalimab
Resistant: C3 – Early Trials
HER-2 amplification
Cholangiocarcinoma
trastuzumab
Sensitive: C3 – Early Trials
DDR
Cholangiocarcinoma
lenvatinib + toripalimab
Sensitive: C3 – Early Trials